In this preclinical study, 100 percent of the animal models were protected from Zika after vaccination followed by a challenge with the Zika virus. In addition, they were protected from degeneration in the cerebral cortex and hippocampal areas of the brain, while the other cohort showed degeneration of the brain after Zika infection.
“Our results support the critical importance of immune responses for both preventing infection as well as ameliorating disease caused by the Zika virus,” said lead researcher David B. Weiner, Ph.D., Executive Vice President and Director of the Vaccine Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research at Wistar. “As the threat of Zika continues, these results provide insight into a new aspect of the possibly protective ability of such a vaccine as a preventative approach for Zika infection.”
This study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals. Prior studies of the Zika virus have tested vaccines in animal models that are naturally resistant to Zika. This study extends these prior research studies in an important manner.
J. Joseph Kim, Ph.D., MBA, President and CEO of Inovio Pharmaceuticals, Inc., added, “Working with Wistar, we have clearly demonstrated the power and the speed of our product development platform when we and our collaborators moved our Zika vaccine from the bench to human studies in less than six months, taking advantage of our platform to help in this outbreak situation.
In this latest study, Weiner and colleagues demonstrated how a synthetic DNA vaccine expressed specific antigens for Zika in vivo. They observed that this novel vaccine generated robust antigen-specific antibody and T cell responses that neutralized the virus in preclinical animal models. Moreover, they found that the vaccine provided protection against the disease and death in animal models while also being neuroprotective, meaning that the disease was unable to spread to the brain. This is especially important given the risk that infants born with the disease have of developing microcephaly, a birth defect resulting in an abnormally small head and that may prevent the brain from developing properly.
One important aspect of Zika and many other mosquito-borne diseases is that not everyone infected with the virus will actually become ill as a result. With Zika, only about 20 to 25 percent of individuals with the virus are actually impacted by the disease, according to previous studies from the U.S. Centers for Disease Control (CDC). However, there is no way to know for certain who will be at risk for illness due to the virus, which is why it was crucial for this study to examine how a vaccine would operate in an infected, symptomatic host.
This Zika vaccine is being developed in collaboration between Inovio, The Wistar Institute, and GeneOne Life Science Inc. and is currently being tested in two human clinical studies. Before the end of 2016, Inovio expects to report phase I data from the first 40-subject study being conducted in Miami, Philadelphia and Quebec City. In August, the companies also initiated a second study in 160 subjects in Puerto Rico. The CDC estimates that Zika will infect more than 25 percent of the Puerto Rican population by the end of the year, creating the potential for this study’s placebo-controlled design to provide exploratory signals of vaccine efficacy in 2017.
A total of nearly 4,000 cases of Zika infection have been reported in the United States alone, according to the CDC. While most of these are travel-associated cases, more than 100 cases of Zika infection originating within the United States have been reported. Globally, more than 60 countries have reported mosquito-borne transmission of the disease.
This work was supported by the National Institutes of Health and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases grant NIH R01 AI092843. Weiner received funding from Inovio Pharmaceuticals Inc. and Gene One Life Science Inc.
Co-authors of this study from The Wistar Institute include Karuppiah Muthumani, Sangya Agarwal, Sagar Kudchodkar, Emma Reuschel, Hyeree Choi, Elizabeth Duperret, Chistopher Chung, and Yinho Kim. Other co-authors of this study include Bryan Griffin, Stephanie Booth, Trina Racine, and Gary Kobinger from the Public Health Agency of Canada; Kim Kraynyak, Jian Yan, Matthew Morrow, Jingjing Jiang, Brian Lee, Stephanie Ramos, Kate Broderick, Charles Reed, Niranjan Y. Sardesai, and J. Joseph Kim from Inovio Pharmaceuticals, Inc.; Amelia Anne Keaton from the Children’s Hospital of Philadelphia; Kenneth Ugen from the University of South Florida Morsani College of Medicine; and Young Park and Joel Maslow from GeneOne Life Science Inc.
###
About The Wistar Institute
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
RSS